

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1477)**

**VOLUNTARY ANNOUNCEMENT**  
**UNAUDITED OPERATING DATA FOR THE YEAR ENDED DECEMBER 31, 2024**

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that certain unaudited operating data of the Group for the year ended December 31, 2024 (the “**Reporting Period**”) and comparative data are set out below.

	The year ended December 31,		change %
	2024 RMB' 000	2023 RMB' 000	
Revenue	408,000-420,000	246,367	65.6-70.5

Reference is made to the Company’s circular dated September 30, 2024 in relation to the extraordinary general meeting (the “**Circular**”). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The significant increase in revenue in 2024 is mainly attributable to: (i) the Company’s completion of the Acquisition of the Transferred Products and the In-Licensing of the Licensed Products, which significantly increased the revenue scale of the Company; (ii) a significant increase in the revenue generated from the sales of other ophthalmic pharmaceutical products by the Company.

During the Reporting Period, the Transferred Products and Licensed Products have brought the following effects on the Company: (i) they not only broadened the Group’s product portfolio, but also brought considerable economic benefits to the Group, especially the dry eye-related products such as Systane® (思然®); (ii) they further strengthened the competitive position of the Company in the field of ophthalmic drugs, especially in the field of dry eye. Based on the extensive experience and market share accumulated, the Company is capable of providing more comprehensive and advanced treatment solutions to further meet the needs of patients and expand the Group’s market share; (iii) by optimizing resource allocation and marketing strategies, and combined with the Company’s strong commercialization and localization capabilities, the Transferred Products and Licensed Products will become a long-term and stable revenue source for the Company.

During the Reporting Period, the sales volume of the Company's core product Youshiying® (優施瑩®) (fluocinolone acetonide intravitreal implant) increased rapidly after being included in the new version of the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance 《國家基本醫療保險、工傷保險和生育保險藥品目錄》. Meanwhile, the commercial team actively expanded the coverage of hospitals, and deeply explored the potential of Ou Qin® (歐沁®), Xalatan® (適利達®) and other products, led to the steady growth of more than ten commercialized products, and therefore captured greater market share.

As of the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the Reporting Period. The above operating information is preliminary unaudited information and has not been reviewed, confirmed or audited by the auditors of the Company, or reviewed by the audit committee of the Board. It is for investors' reference only, and shall not be considered as a measure or indicator of the future financial performance of the Group. Shareholders and potential investors are advised to read carefully the results announcement of the Company in respect of the Group for the Reporting Period, which is expected to be released in March 2025 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, February 12, 2025

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.*